Navigation Links
Senetek PLC Announces Positive Results from Pyratine-6(TM) Clinical Trial in Patients with Acne Rosacea
Date:5/5/2008

Accepted for Presentation at the International Investigative Congress of

Dermatology at May 2008 meeting in Kyoto, Japan

NAPA, Calif., May 5 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced positive study results from a clinical trial of Pyratine-6(TM) in patients with acne rosacea. The findings have been accepted for presentation at the International Investigative Congress of Dermatology at its May 2008 meeting in Kyoto, Japan.

Based on positive results demonstrated in previous studies of Pyratine-6(TM) (0.1%), for the remediation of photodamaged skin and erythema which included unprecedented reduction in facial redness, in as early as two weeks, an additional study was initiated for acne rosacea. The follow up study was designed to extend these significant clinical findings by assessing the effects of Pyratine-6(TM) (0.125%) in improving clinical signs and symptoms of acne rosacea. Twenty-four subjects with mild-to-moderate acne rosacea participated in the 12 week study. Subjects were evaluated at baseline, 4, 8 and 12 weeks. Evaluations included physician assessments of inflammatory lesion count, severity of erythema and telangiectasia, and overall clinical improvement. Patient assessments of signs and symptoms of rosacea and skin tolerance were also rated at each follow-up. In addition, transepidermal water loss measurements and facial photography were conducted at each visit.

Pyratine-6(TM) produced a progressive decrease in the symptoms associated with rosacea including redness and acne lesions. All subject self-assessments showed good tolerability and cosmetic acceptability. After 12 weeks there was overall clinical improvement in 80% of subjects, including reduction of erythema and papules. Transepidermal water loss measurements showed a 22% decrease in water loss, which supports an improvement in skin barrier function. In view of the promising results, the current study has been extended to 48 weeks.

Rosacea is a common chronic facial dermatosis, affecting 14 million Americans, that is characterized by persistent erythema, telangiectasia, papules and pustules. Patients with rosacea are often unable to tolerate extended treatment periods with topical agents as a result of skin sensitivity that accompanies rosacea. Due to the chronic nature of rosacea, there is a continuing need for efficacious treatments that provide sustained relief of its principal signs and symptoms.

Dr. Arisa Ortiz from the University of California Irvine, who is presenting the results of this study at the 2008 International Investigative Dermatology meeting in Kyoto, Japan, stated, "All study subjects reported good tolerability and cosmetic acceptability to Pyratine-6 (TM). The majority of subjects showed reductions in erythema, papules, burning, stinging, and dryness, all of which are signs and symptoms associated with acne rosacea. Transepidermal water loss measurements showed a decrease in water loss which supports an improvement in skin barrier function, attesting to the moisturizing properties of this compound."

Commenting on these findings, Frank Massino, Senetek Chairman and Chief Executive Officer stated, "We are pleased by the positive study findings as this further confirms the excellent safety and effectiveness profile of Pyratine-6(TM). Response to Pyratine-6(TM) in the U.S. physician market has been outstanding and we look forward to expanding our sales and marketing efforts to accommodate increasing demand for this important product."

About Senetek PLC

Senetek PLC (OTCBB: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market.

For more information, visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2007. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek, PLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016 ... titled, "Skincare Devices Market - Global Industry Analysis, Size, ... to the report, the global skincare devices market was ... anticipated to expand at a CAGR of 10.1% from ... 2023. Browse the full Skincare Devices Market (Treatment ...
(Date:4/27/2016)... April 27, 2016  Bayer Animal Health today ... from the University of Florida College of Veterinary ... Excellence in Communication Award (BECA). Brittany was selected ... awarded a total of $70,000 in scholarship funds ... years, Bayer has provided a total of $232,500 ...
(Date:4/27/2016)... , April 27, 2016 ... ), a developer of a new generation of ... positive overall survival results for Paclical/Apealea in the ... 789 patients with epithelial ovarian cancer. These preliminary ... Paclical/Apealea in combination with carboplatin versus Taxol in ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... , ... Our bodies are bombarded daily by environmental and lifestyle factors that ... is to adopt a more healthful diet, but too many people think that food ... Nutritionist and the creator of the Newport Beach Cleanse and 14-Day Eating Plan, disagrees ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s ... Sunday, with sunny skies, a light breeze and temperatures in the 60s. Over 400 ... 5k Run and Walk and 1-mile walk were held to increase awareness about ...
(Date:4/29/2016)... Kansas City, Missouri (PRWEB) , ... April 29, 2016 , ... ... Unlike traditional crutches which put pressure on the armpits, the M+D Crutch evenly distributes ... less strain on their wrists and hands when using the crutches than with other ...
(Date:4/29/2016)... , ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon ... is a very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to ... is a procedure that involves one or both jaw bones. This surgery is performed to ...
(Date:4/29/2016)... ... April 29, 2016 , ... Regenerative Medicine Solutions (RMS) scored ... satisfaction survey, earning them second place for Tampa’s Best Places to Work. They were ... “This is a great accomplishment for our team,” says RMS Human Resources Manager Irene ...
Breaking Medicine News(10 mins):